Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1209

Shown on this page

Current sort

Live official records

Conditions: Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Enfortumab vedotin, Pembrolizumab; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Duarte, California • Indianapolis, Indiana • New York, New York + 1 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Interventions: Pembrolizumab, Patient Observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment; Biological · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 828
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 600 more

Conditions: Pre-Bronchiolitis Obliterans Syndrome
Interventions: ARINA-1, Standard of care only; Drug · Other
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Interventions: DB-OTO; Genetic
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 6 more

Conditions: Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
Interventions: Continuous Positive Airway Pressure, Sleep Advice Control; Device · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 55 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: Risankizumab, Vedolizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more

Conditions: Stillbirth
Interventions: Not listed
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: San Diego, California • New York, New York • Portland, Oregon + 2 more

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Interventions: Acoramidis, Placebo oral tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 40
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 31 more

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, RFC1 Gene Mutation, Spinocerebellar Ataxia Type 27b, Healthy Participants
Interventions: Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, Assessments and Questionnaires, Cerebrospinal Fluid Collection; Genetic · Other
Lead sponsor: Lauren Moore; Other
Eligibility: 6 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 12 more

Conditions: Coronary Arterial Disease (CAD)
Interventions: Intravascular Lithotripsy; Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 28
States / cities: La Jolla, California • San Francisco, California • Littleton, Colorado + 19 more

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 107
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more

About this Columbia University Irving Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Columbia University Irving Medical Center

Filter and sort this campus

Live official records

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

Autoimmune Features of Neurodegenerative Disorders

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Research On Advanced Diagnostics and Management of All Pregnancies to Prevent Stillbirth (ROADMAPS)

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

FORWARD CAD IDE Study

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

About this Columbia University Irving Medical Center institution page